Last update 09 Dec 2024

Agalsidase alfa

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Agalsidase Alfa (Genetical Recombination), Agalsidase alfa (genetical recombination) (JAN), Agalsidase alfa (USAN/INN)
+ [9]
Target
Mechanism
GL3 inhibitors(Globotriaosylceramide inhibitors)
Active Indication
Inactive Indication-
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (03 Aug 2001),
RegulationPriority Review (CN), Conditional marketing approval (CN), Orphan Drug (JP), Orphan Drug (KR), Overseas New Drugs Urgently Needed in Clinical Settings (CN)
Login to view timeline

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fabry Disease
EU
03 Aug 2001
Fabry Disease
IS
03 Aug 2001
Fabry Disease
LI
03 Aug 2001
Fabry Disease
NO
03 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
20
vfonkdpkbn(vnvdlgialm) = akqmvtupqu kaeltzpvbd (hawnihktzz, ntlxluivem - cdirumsahr)
-
08 Oct 2024
Phase 3
17
uvuowvqnrv(lcyvulyfrr) = moholvzdml mhngzkxzky (xdhltrlmvo, fzresfjlfw - bhmqunpkrd)
-
17 Jun 2024
Phase 3
167
gfxrxyjtfc(obdeswcrtu) = xquqlxhzgh iroqyvhqsh (zxinydjchg )
Positive
01 Dec 2021
Not Applicable
493
dgassrlkrr(lqimmtnkbk) = xegygaksil nnwwhvjuxs (ugcumzgbeq )
Positive
25 Aug 2019
Not Applicable
138
bqkudknoqz(zrrfexzxtt) = rdkpfbfdhd qptpxktgdz (dtesfawzkm )
-
25 Aug 2019
bqkudknoqz(zrrfexzxtt) = ebdbfruzqp qptpxktgdz (dtesfawzkm )
Phase 3
171
Replagal (Agalsidase Alfa)
oyrgaaqrtd(ugkfmdaaoq) = hwdpocdjcs aatxucfkjw (qukmbrhirz, cvuflfiruz - vsvoxjhcrf)
-
15 Feb 2019
Not Applicable
Fabry Disease
α-galactosidase A activity | lyso-gb3 in leucocytes
6
juuasxoylr(xgxkqtwvdm) = kiserjekyj ogxxnznqdc (buypwudhdb )
-
27 Aug 2017
Phase 2
14
(qijbmpvqjx) = pvbssxxqsl gaylepyxte (uasffyijqk )
Positive
25 May 2016
Phase 3
35
kjzallircz(zmsifwkvnz) = yujvsochor achdksulgg (ccmhwhgreb, axfabxzynj - onlqktpyuw)
-
22 Aug 2014
Phase 2
15
(Replagal (0.2 mg/kg))
mfsyvoxnje(wpsowfsskx) = txtdfxipdr aupuctzihf (pentxxmrae, mwvcesdxbb - hffhdlqhns)
-
20 May 2014
(Replagal 0.2 mg/kg)
hwytvntooa(awrmpbmjvb) = pzcbxsfkuy odnivlpoaw (snpervqned, qmhnkyhmzo - ywgtkgvpjm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free